Therapeutic Use of Native and Recombinant Enteroviruses
Open Access
Abstract
Research on human enteroviruses has resulted in the identification of more than 100 enterovirus types, which use more than 10 protein receptors and/or attachment factors required in cell binding and initiation of the replication cycle. Many of these “viral” receptors are overexpressed in cancer cells. Receptor binding and the ability to replicate in specific target cells define the tropism and pathogenesis of enterovirus types, because cellular infection often results in cytolytic response, i.e., disruption of the cells. Viral tropism and cytolytic properties thus make native enteroviruses prime candidates for oncolytic virotherapy. Copy DNA cloning and modification of enterovirus genomes have resulted in the generation of enterovirus vectors with properties that are useful in therapy or in vaccine trials where foreign antigenic epitopes are expressed from or on the surface of the vector virus. The small genome size and compact particle structure, however, set limits to enterovirus genome modifications. This review focuses on the therapeutic use of native and recombinant enteroviruses and the methods that have been applied to modify enterovirus genomes for therapy.Keywords
This publication has 81 references indexed in Scilit:
- Endocytosis of Integrin-Binding Human PicornavirusesAdvances in Virology, 2012
- Myeloma Xenograft Destruction by a Nonviral Vector Delivering Oncolytic Infectious Nucleic AcidMolecular Therapy, 2011
- Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18Virology Journal, 2011
- ViralZone: a knowledge resource to understand virus diversityNucleic Acids Research, 2010
- A Single Coxsackievirus B2 Capsid Residue Controls Cytolysis and Apoptosis in Rhabdomyosarcoma CellsJournal of Virology, 2010
- Picornaviruses2010
- Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiformeCytokine & Growth Factor Reviews, 2010
- Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vectorVaccine, 2009
- Recombinant Oncolytic Poliovirus Eliminates Glioma In Vivo Without Genetic Adaptation to a Pathogenic PhenotypeMolecular Therapy, 2008
- Integrin αvβ3‐targeted cancer therapyDrug Development Research, 2008